Key result
Levosimendan improves hemodynamics and symptoms in ADHF without increasing myocardial oxygen consumption.
Why the study?
Despite numerous publications on levosimendan in acute decompensated heart failure, some issues related to its application remain unclear.
This review summarizes current expert recommendations and literature on the use of levosimendan for acute decompensated heart failure.
No takes yet. Share an insight, caveat, or question.
May support levosimendan in acute decompensated HF; leaves open optimal selection and dosing pending trials.
Glinka et al. (2019) conducted a review in Acute decompensated heart failure. Levosimendan vs. Classical inotropic drugs was evaluated. Levosimendan improves hemodynamic parameters and clinical symptoms in acute decompensated heart failure of various etiologies without significantly increasing myocardial oxygen consumption.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: